C22orf39

Across TCGA pan-cancer cohorts, C22orf39 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of C22orf39’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where C22orf39 RNA is repressed in tumor relative to normal tissue. In most cancer types C22orf39 is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

THCA, LUAD, and LIHC are the cancer types where C22orf39 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C22orf39 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−1.137	<.001	11	view →
LUAD	Female	III,IV	−0.878	<.001	9	view →
LIHC	Female	II,III,IV	+0.661	<.001	9	view →
BLCA	All	IV	−1.235	.002	8	view →
LUSC	All	III,IV	−0.821	<.001	8	view →
KICH	Female	All	−0.865	<.001	7	view →
BRCA	All	II,III,IV	−0.717	<.001	6	view →
KIRC	Male	III,IV	−0.397	<.001	6	view →
KIRP	All	All	−0.383	<.001	4	view →
CHOL	Male	All	+1.413	<.001	2	view →
UCEC	All	All	−0.828	<.001	2	view →
READ	All	All	−0.712	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

C22orf39–THCA

Open the THCA breakdown →